# A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

> **NCT02951117** · PHASE1 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** ABBV-838
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02951117
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-08-31
- **Primary completion:** 2020-07-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951117, "A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02951117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*